It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Understanding and treating disorders of the central nervous system (CNS) is one of science’s greatest challenges. Neurological, psychiatric, and neurodevelopmental conditions are highly diverse and affect billions of people worldwide. At Sygnature Discovery, we integrate advanced models, assays, and global scientific expertise to accelerate CNS drug discovery.
The CNS is complex, with hundreds of disorders and unique barriers such as the blood-brain barrier (BBB) that limit drug penetration. We embrace this complexity through a disease-agnostic approach, recognizing similar molecular, cellular and pathway mechanisms across CNS disorders and navigating the BBB challenge.
Over the past decade, we have made significant investments in our neuroscience department, building specialist expertise in complex mechanisms that drive our assay development, model innovation, and integrated project approaches across our collocated teams. Our mission is to make discovery faster, smarter, and more connected, ensuring that new therapies reach patients sooner.
Why choose Sygnature Discovery for Neuroscience Support?
Our neuroscience ecosystem is built on eight pillars, offering assays and models that can be adapted or customized for any bespoke CNS program, enabling us to advance therapeutics across a broad range of CNS disorders.
With state-of-the-art instrumentation across Chemistry, Bioscience, DMPK, and in vivo pharmacology, we deliver robust, automated, scalable solutions that accelerate discovery without compromising quality.
Platforms & Capabilities
We offer state-of-the-art in vitro and in vivo solutions designed to advanced neuroscience:
in vitro Assays
MitochondrialHealth Calcium flux, membrane potential, oxygen consumption, metabolism, and bio genesis. Learn more >
LysosomalFunction Quantification, pH , enzymatic activity, and autophagic flux
Neuroinflammation Cytokine release, phagocytosis
Neuroplasticity Pre and post synaptic markers, neurite outgrowth, neuro chemical endpoints
in vivo Models
LPS -Induced Neuro inflammation Cytokines, microglial activation, TSPO expression in the brain
PhenotypicModels For substance abuse and psychiatric symptom surrogates
Our integrated in vivo and DMPK teams analyze blood and brain PK data and develop comprehensive PK/PD understanding to model and predict human translation.
Translational Biomarkers
For early clinical proof of mechanism or concept, we measure biomarkers relevant to CNS disorders in brain and biofluids of wild-type and transgenic mice including A β40 -42, total Tau and pTau, NfL, cytokines, monoamines, acetylcholine, glutamate, GABA, and ex vivo binding to various targets for which human PET ligands are available.
Our cutting-edge in vitro assay platform is tailored for advancing neuroscience drug discovery.
Want to scale up human disease models with unmatched cellular quality, and disease relevance to increase confidence in clinical translations?
Contact us about our humanized neuroinflammation in vitro platform, SCANME.
Human iPSC-Derived Cells Bringing research closer to human disease for greater translational confidence.
HighContent Imaging & Bespoke Assays Including excitotoxicity and microglia-based neuroinflammation platforms.
Computational Chemistry Optimizing brain-penetrant drug design.
DMPKGuidance Comprehensive PK/PD modelling for CNS exposure for CNS exposure and target engagement.
Our Neuroscience Lead Consultant
Max Mirza, PhD
Vice President, Neuroscience Drug Discovery
Max Mirza is a neuroscientist who has worked in Biotech, Big & Midsize Pharma for over 25 years, including NeuroSearch, Pfizer, and Mundipharma. He has worked on multiple assets
that have progressed to all stages of clinical development, including Phase 3, in areas of neuroscience, pain, metabolic
disorders, and infectious disease. He was a founder and CSO of the Biotech Saniona (Nasdaq, Stockholm) and
consults for VCs and investment teams on translational and clinical approaches in neuroscience. He has a PhD in
Neuroscience from the Institute of Psychiatry, University of London. Read More
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
